Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients Yvonne C.W. Yau, Felix Ratjen, Elizabeth Tullis,

Slides:

Advertisements

Similar presentations

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

Dietary supplementation with multiple micronutrients: No beneficial effects in pediatric cystic fibrosis patients Johanna H. Oudshoorn, Peter H.C. Klijn,

William G. Flight, Jonathan Shaw, Susan Johnson, A

Felix Ratjen, Paul Koker, David E

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

The ease of breathing test tracks clinical changes in cystic fibrosis

Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis T.W.V. Daniels, G.B. Rogers, F.A. Stressmann, C.J.

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Pulmonary exacerbations in CF patients with early lung disease

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

Molecular detection of an atypical, highly resistant, clonal Pseudomonas aeruginosa isolate in cystic fibrosis patients Deirdre Keating, Mary J. Crowe,

Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients J.L. Fothergill,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Physiologic endpoints for clinical studies for cystic fibrosis

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Valerie Waters, Eshetu G

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas.

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions Gerard McCaughey,

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients Valerie Waters, Eshetu G. Atenafu, Annie.

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Higher risk of hospitalization among females with cystic fibrosis

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis C. Calabrese, A. Tosco, P. Abete, V. Carnovale,

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate.

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation Noa Nezer M. Sc, David Shoseyov, Eitan.

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients Yvonne C.W. Yau, Felix Ratjen, Elizabeth Tullis, Pearce Wilcox, Andreas Freitag, Mark Chilvers, Hartmut Grasemann, James Zlosnik, David Speert, Mary Corey, Sanja Stanojevic, Larissa Matukas, Timothy Ronan Leahy, Sarah Shih, Valerie Waters Journal of Cystic Fibrosis Volume 14, Issue 2, Pages 262-266 (March 2015) DOI: 10.1016/j.jcf.2014.09.013 Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 CONSORT flow chart. Selection of study population and drop outs. N=number of patients; n=number of exacerbations. PA: Pseudomonas aeruginosa. Journal of Cystic Fibrosis 2015 14, 262-266DOI: (10.1016/j.jcf.2014.09.013) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Mean change in sputum Pseudomonas aeruginosa density (log10colonyformingunits (CFU)/ml) from day 0 to day 14 of antibiotic treatment and to the 1month follow-up visit (±standard error of the mean) for all 74 pulmonary exacerbations. Conventional group: open circle, biofilm group: closed square. Journal of Cystic Fibrosis 2015 14, 262-266DOI: (10.1016/j.jcf.2014.09.013) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Mean change in A) forced expiratory volume in 1s (FEV1) (L) and B) forced vital capacity (FVC) (L) from day 0 to day 7, 14 of antibiotic treatment and to the 1month follow-up visit (±standard error of the mean) for all 74 pulmonary exacerbations. Conventional group: open circle, biofilm group: closed square. Journal of Cystic Fibrosis 2015 14, 262-266DOI: (10.1016/j.jcf.2014.09.013) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions